Kathryn Waldrep
Obstetrics & Gynecology · Dallas, TXNPI 1396738092
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,313 of the $4,100 with a category attached, or 80.8%. 44 manufacturers reported payments, led by Coloplast at 24.4% of the total. Reporting peaked in 2019 at $1,495 and has fallen 72.9% since, to $405 in 2025.
Across 180 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1000
- Astellas Pharma US Inc$382
- AbbVie$317
- Pfizer$212
- Amgen$186
- Exeltis, USA Inc.$161
- plus $2K from 38 others
Across 8 payments — averaging $3018.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$20K
- Bayer$3K
- Boston Scientific$1K
What the payments were for
- Travel & lodging$61215%
- Food & beverage$3,31381%
- Education$1574%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$768
How this compares
$4,100 in reported general payments places this provider in the 80th percentile of 3,099 obstetrics & gynecology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol (Twice Weekly)Estradiol | 101 | $11,828 |
| PremarinEstrogens, Conjugated | 24 | $11,740 |
| Estradiol | 143 | $9,250 |
| EstringEstradiol | 17 | $8,761 |
| ImvexxyEstradiol | 14 | $7,647 |
| DottiEstradiol | 56 | $6,916 |
| YuvafemEstradiol | 41 | $5,809 |
| OsphenaOspemifene | 11 | $3,063 |
| SynthroidLevothyroxine Sodium | 21 | $1,701 |
| Estradiol (Once Weekly)Estradiol | 12 | $1,161 |
| Escitalopram Oxalate | 44 | $838 |
| ValacyclovirValacyclovir Hcl | 41 | $767 |
| ProgesteroneProgesterone, Micronized | 29 | $531 |
| Bupropion XlBupropion Hcl | 12 | $458 |
| Levothyroxine Sodium | 29 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Estring | $212 | $20,50141 claims |
| Therapeuticsmd, Inc.Imvexxy | $105 | $7,64714 claims |
| Duchesnay USA IncorporatedOsphena | $20 | $3,06311 claims |
| AbbVieSynthroid | $317 | $1,70121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,099 obstetrics & gynecology providers in Texas.
Other obstetrics & gynecology in Dallas
- Dale StovallDallas$590K
- Quanita CrableDallas$176K
- Kamilia SmithDallas$119K
- Yolanda LawsonDallas$96K
- Patrick WeixDallas$96K
- David RogersDallas$44K
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.